...

ADI-PEG 20 or Placebo Plus Gemcitabine and Docetaxel in Previously Treated Subjects with Leiomyosarcoma (ARGSARC): A Randomized, Double-Blind, Multi-Center Phase 3 Trial

To compare the efficacy and safety in subjects with advanced or metastatic LMS previously treated with an anthracycline.


Why this Research Matters

This is a global, multicenter, randomized, double-blind, placebo-controlled, parallel-group phase 3 trial that will compare the efficacy and safety in subjects with advanced or metastatic LMS previously treated with an anthracycline.


Who can Participate

Adult

Detailed eligibility criteria is available on clinicaltrials.gov. These requirements will be discussed with your doctor and/or study representative. Click the NCT number link below to learn more about this study on ClinicalTrials.gov


Study ID

Protocol Number: 23-1728
More information available at ClinicalTrials.gov: NCT05712694

Meet the Team

Image of Principal Investigator

Breelyn Wilky, MD

Principal Investigator